Heregulin regulates prolactinoma gene expression.
To investigate the role of p185(her2/neu)/ErbB3 signaling in pituitary tumor function, we examined these receptors in human prolactinomas. Immunofluorescent p185(her2/neu) was detected in almost all (seven of eight), and ErbB3 expression in a subset (four of eight) of tumors (seven adenomas and one carcinoma). Quantitative PCR also showed abundant ErbB3 mRNA in tumor specimens derived from a rarely encountered prolactin-cell carcinoma. Activation of p185(c-neu)/ErbB3 signaling with heregulin, the ErbB3 ligand, in rat lacto-somatotroph (GH4C1) tumor cells specifically induced prolactin (PRL) mRNA expression approximately 5-fold and PRL secretion approximately 4-fold, whereas growth hormone expression was unchanged. Heregulin (6 nmol/L) induced tyrosine phosphorylation and ErbB3 and p185(c-neu) heterodimerization, with subsequent activation of intracellular ERK and Akt. The Akt signal was specific to ErbB3 activation by heregulin, and was not observed in response to epidermal growth factor activation of epidermal growth factor receptor. Gefitinib, the tyrosine kinase inhibitor, suppressed heregulin-mediated p185(c-neu)/ErbB3 signaling to PRL. Heregulin induction of PRL was also abrogated by transfecting cells with short interfering RNA directed against ErbB3. Pharmacologic inhibition of heregulin-induced phosphoinositide-3-kinase/Akt (with LY294002) and ERK (with U0126) signaling, as well as short interfering RNA-mediated mitogen-activated protein kinase-1 down-regulation, showed ERK signaling as the primary transducer of heregulin signaling to PRL. These results show ErbB3 expression in human prolactinomas and a novel ErbB3-mediated mechanism for PRL regulation in experimental lactotroph tumors. Targeted inhibition of up-regulated p185(c-neu)/ErbB3 activity could be useful for the treatment of aggressive prolactinomas resistant to conventional therapy.
Vlotides
George
G
Department of Medicine, Cedars-Sinai Medical Center, University of California School of Medicine, Los Angeles, CA, USA.
Cooper
Odelia
O
Chen
Yen-Hao
YH
Ren
Song-Guang
SG
Greenman
Yona
Y
Melmed
Shlomo
S
D000199:Actins / Q000235:genetics; D000818:Animals; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D005966:Glucuronidase / Q000235:genetics; D005987:Glyceraldehyde-3-Phosphate Dehydrogenases / Q000235:genetics; D013006:Growth Hormone / Q000378:metabolism; D006801:Humans; D020890:Neuregulin-1 / Q000494:pharmacology*; D010902:Pituitary Gland / Q000187:drug effects / Q000502:physiology; D010911:Pituitary Neoplasms / Q000201:enzymology / Q000235:genetics*; D016133:Polymerase Chain Reaction; D011388:Prolactin / Q000378:metabolism; D015175:Prolactinoma / Q000201:enzymology / Q000235:genetics*; D034741:RNA, Small Interfering / Q000235:genetics; D051381:Rats; D011920:Rats, Inbred WF; D014162:Transfection; D001613:beta 2-Microglobulin / Q000235:genetics
D000199:Actins; D020890:Neuregulin-1; D034741:RNA, Small Interfering; D001613:beta 2-Microglobulin; D011388:Prolactin; D013006:Growth Hormone; D005987:Glyceraldehyde-3-Phosphate Dehydrogenases; D005966:Glucuronidase